# Quality Assurance Report

## Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0174 |
| PP ID | PP-0174 |
| Title | Screening Harms and False Results |
| Version | 1.0.0 |
| Status | PASS — GOLD |

# Layer 1 — Content QA

| Criterion | Result | QA Note |
|---|---|---|
| One atomic clinical question | PASS | Focused on screening harms and false results |
| Approved scope preserved | PASS | No material scope expansion |
| False-positive framework complete | PASS | Definition, consequence, PPV, example |
| False-negative framework complete | PASS | Definition, false reassurance, limitation |
| Screening versus diagnosis distinction | PASS | Explicitly preserved |
| Procedural harms | PASS | Endoscopy complications included |
| Radiation harm | PASS | Photofluorography included |
| Premedication | PASS | Included at appropriate level |
| Overdiagnosis | PASS | Clearly separated from false positive |
| Overtreatment | PASS | Presented as downstream consequence |
| Population context | PASS | Linked to PP-0173 |
| Center-experience context | PASS | Included |
| Common misconceptions | PASS | 10 patient-facing myths |
| Key messages | PASS | 12 concise messages |
| Knowledge Graph | PASS | Prerequisite / related / next defined |

# Layer 2 — Clinical QA

| Criterion | Result | QA Note |
|---|---|---|
| NCI Screening PDQ used as primary evidence | PASS | Direct source for harm claims |
| False-positive harm represented accurately | PASS | Most frequent reported harm |
| Endoscopic harms represented accurately | PASS | Rare but serious |
| Perforation included | PASS | Source-supported |
| Bleeding included | PASS | Source-supported |
| Cardiopulmonary events included | PASS | Source-supported |
| Aspiration pneumonia included | PASS | Source-supported |
| Photofluorography radiation represented accurately | PASS | Approximately 0.6 mSv in cited evidence |
| Radiation risk uncertainty preserved | PASS | Theoretical / poorly quantified |
| Premedication adverse effects | PASS | Source-supported |
| Overdiagnosis/overtreatment | PASS | Source-supported |
| Screening-center experience | PASS | Source-supported |
| Japanese PPV example | PASS | 0.85%, study-specific |
| Cancer detection rate example | PASS | 0.28%, study-specific |
| No universal PPV invented | PASS | Explicitly prohibited |
| No universal NPV invented | PASS | Explicitly prohibited |
| No universal sensitivity/specificity invented | PASS | Explicitly prohibited |
| No universal complication rate invented | PASS | Explicitly prohibited |
| No unsupported screening interval | PASS | Excluded |
| No individualized screening advice | PASS | Excluded |
| No treatment recommendation | PASS | Outside scope |

# Layer 3 — Educational QA

| Criterion | Result | QA Note |
|---|---|---|
| Plain language | PASS | Patient-facing wording |
| One concept per block | PASS | 20 independent knowledge blocks |
| Medical terminology explained | PASS | PPV, overdiagnosis, false results explained |
| Neutral tone | PASS | No alarmist language |
| Uncertainty visible | PASS | Evidence gaps explicit |
| Screening vs diagnosis clear | PASS | Repeated at key points |
| False positive vs overdiagnosis distinguished | PASS | Explicitly separated |
| Patient safety emphasized | PASS | Harm/benefit balance |
| Misconceptions addressed | PASS | 10 myths |
| No unsupported certainty | PASS | Study-specific values clearly labeled |

# Layer 4 — Governance QA

| Criterion | Result | QA Note |
|---|---|---|
| CKO completed | PASS | Full Gold structure |
| Knowledge Passport completed | PASS | Full governed metadata |
| Evidence Package completed | PASS | Full evidence architecture |
| QA Report completed | PASS | Four-layer QA |
| Source-first rule | PASS | Source Files reviewed |
| Approved Decision Batch preserved | PASS | Scope unchanged |
| Gold reference depth | PASS | Expanded to full reference depth |
| Gold structure preserved | PASS | No architecture redesign |
| Evidence traceability | PASS | Claim-to-source matrix |
| Boundary | PASS | Clean four-part ownership boundary |
| Adjacent PP overlap | PASS | Explicitly checked |
| Knowledge Graph | PASS | Connected |
| Versioning | PASS | 1.0.0 |
| Repository readiness | PASS | ZIP package produced |

# Clinical Safety QA

## Screening Result Safety

**PASS**

The package does not equate:

- positive screening with cancer;
- negative screening with absence of cancer.

## Procedural Safety

**PASS**

Procedural complications are described as potential and, where source-supported, rare but serious.

## Radiation Safety

**PASS**

Radiation exposure is described quantitatively only in the source-supported context and the carcinogenesis uncertainty is preserved.

## Overdiagnosis Safety

**PASS**

Overdiagnosis is distinguished from false-positive testing and is not converted into treatment advice.

## Population Safety

**PASS**

The package does not assume that evidence from high-incidence settings automatically applies to low-incidence populations.

# Evidence Traceability QA

## Direct Claims

The following claims are directly traceable to the NCI Screening PDQ:

1. False-positive testing is the most frequent reported harm.
2. Screening harms are poorly quantified/reported overall.
3. Photofluorography exposes patients to low-dose radiation.
4. Radiation carcinogenesis risk is theoretical and poorly quantified.
5. Premedication can cause adverse effects.
6. Endoscopy can cause bleeding and perforation.
7. Endoscopy can cause cardiopulmonary events and aspiration pneumonia.
8. Overdiagnosis may lead to overtreatment.
9. Some complications vary with screening-center experience.
10. The Japanese program had PPV 0.85%.
11. The Japanese program had cancer detection rate 0.28%.
12. No mortality reduction was observed in that program over seven years versus the age-matched surrounding population.

## Claims Intentionally Not Quantified

- Universal false-positive rate
- Universal false-negative rate
- Universal PPV/NPV
- Universal sensitivity/specificity
- Universal complication rate
- Universal overdiagnosis rate
- Universal psychological-harm rate
- Universal cost burden

# Boundary QA

## Core

- False-positive and false-negative results
- Screening result versus diagnosis
- PPV concept
- Downstream consequences
- False reassurance
- Endoscopic harms
- Photofluorography radiation
- Premedication adverse effects
- Overdiagnosis/overtreatment
- Center experience
- Population-dependent benefit–harm balance
- Evidence limitations

## Supporting

- Anxiety/uncertainty
- Time/resource burden
- Interval/missed cancer concept
- Conceptual sensitivity/specificity
- Population context from PP-0173

## Explicitly Excluded

- Detailed modality technique
- Detailed diagnostic work-up
- Biopsy/pathology
- Universal performance metrics
- Universal screening schedules
- Individualized recommendations
- Detailed treatment harms
- Detailed economics

## Delegated-to PP

- PP-0165
- PP-0166
- PP-0167
- PP-0169
- PP-0170
- PP-0171
- PP-0172
- PP-0173
- PP-0175
- PP-0176
- PP-0177
- PP-0178+
- Downstream treatment packages

# Architecture QA

The package occupies the correct position:

**PP-0170 — Individual high-risk screening**

↓

**PP-0171 — Endoscopic screening**

**PP-0172 — Serum pepsinogen**

↓

**PP-0173 — High-incidence population context**

↓

# **PP-0174 — Screening harms and false results**

↓

**PP-0175 — Diagnostic work-up**

This prevents three major forms of duplication:

1. screening eligibility;
2. screening modality technique;
3. diagnostic work-up.

# Gold Depth QA

The re-produced package was deliberately expanded to match the project's approved Gold reference depth rather than using a compact artifact style.

### CKO

Includes:

- full metadata;
- 10 educational objectives;
- detailed included/excluded scope;
- 20 independent clinical knowledge blocks;
- patient explanations;
- clinical importance;
- key concepts;
- 10 misconceptions;
- 12 key messages;
- prerequisite/related/downstream Knowledge Graph;
- revision history.

### Knowledge Passport

Includes:

- identity;
- detailed classification;
- patient journey;
- runtime usage;
- retrieval intent/tags;
- Knowledge Graph;
- core/supporting/excluded/delegated scope;
- authoritative sources;
- evidence classification;
- governance metadata;
- version control;
- change history.

### Primary Evidence Package

Includes:

- clinical question;
- educational intent;
- scope;
- primary/supporting sources;
- evidence hierarchy;
- detailed evidence matrix;
- evidence notes;
- evidence-supported clinical model;
- evidence-strength classification;
- clinical claims summary;
- consistency review;
- evidence gaps;
- delegation;
- future update triggers;
- source traceability;
- boundary verification;
- final status.

### QA Report

Includes:

- four QA layers;
- clinical safety QA;
- evidence traceability QA;
- boundary QA;
- architecture QA;
- Gold depth QA;
- final decision.

# Final QA Decision

## PASS

PP-0174 has been re-produced as a **full-depth Gold Population Package**, not a compact version.

The artifact set is structurally and substantively aligned with the project's locked Gold specification and approved Source File references.

# QA Final Status

**PASS — GOLD — READY FOR INTEGRATION.**
